Results - Announcements
Bharat Parenterals Ltd share price inched up 1.83% to Rs 1918.7 after the company's net profit plunged by 432.02% to Rs 11.82 crore, while revenue from operations gained significantly 45.38% to Rs 136.28 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.28%. It has improved by 3.87% over last one week and moved up slightly by 0.06% in last one month while the market capitalization of Bharat Parenterals Ltd has marginally improved by 7.25% and 30.53% in the same period respectively.
Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 14.0 crore in Q3 FY26, crashing by 291.52% year-on-year, and plunging by 1039.60% quarter-on-quarter. EBITDA came in at Rs 21 crore, tumbling by 876.38% YoY and expanding by 183.18% sequentially.
Total expenses soared by 29.63% to Rs 121.71 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 60.27 crore, witnessing a sharp rise of 48.81% YoY, while employee benefits expense was at Rs 21.43 crore, jumping 13.75% YoY.
For the TTM ended FY26, revenue from operations grew marginally by 1.48% to Rs 345.43 crore, while net profit tanked by 37.48% to Rs 27.31 crore, compared to previous TTM. EBITDA saw a sharp decline of 1099% to Rs 6.28 crore, and PBT collapsed by 36.91% to Rs 21.42 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 38.36 crore in FY26, as against Rs 27.25 crore in FY25.
Bharat Parenterals Ltd surged by 54.12% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.